A/Prof Andrew Jabbour

bio-andrew_jabbour

Associate Professor Andrew Jabbour is a Consultant Cardiologist at St Vincent’s Hospital, Sydney, and a conjoint Associate Professor of Medicine with the University of New South Wales. After completing cardiology training at St Vincent’s, Dr Jabbour undertook a PhD at the Victor Chang Cardiac Research Institute before moving to the United Kingdom to work at The Royal Brompton Hospital and Imperial College London.

In his years overseas Dr Jabbour gained further expertise in advanced cardiovascular imaging. At the world’s largest and most established Cardiac MRI unit, he also conducted research with a particular focus on cardiomyopathy (from coronary artery disease and genetic causes), hypertension, valvular heart disease, and rarer infiltrative disorders such as cardiac amyloidosis and sarcoidosis. This work has been published in the highest ranking medical journals, including the Journal of the American College of Cardiology, The Lancet and JAMA.

He has received numerous awards for his work including the University of New South Wales Foundation Year Graduates Medal, the Transplantation Society of Australia and New Zealand President’s Prize, and a prestigious National Health and Medical Research Council of Australia Neil Hamilton-Fairley Postdoctoral Clinical Research Fellowship.

Dr Jabbour is a member of the Heart Transplantation Team at St Vincent’s Hospital. He also works as a general cardiologist, travelling with New South Wales Royal Flying Doctors Service (Rural Doctors Network). He has a keen interest in radiation-free cardiac imaging and runs a weekly Cardiac MRI session at St Vincent’s Hospital.

 

 

  • MBBS (Hons), PhD, FRACP, FCSANZ.
  • Cardiologist & Cardiovascular Imaging Specialist, St Vincent’s Hospital, Sydney
  • Conjoint Associate Professor of Medicine, University of New South Wales
  • Clinical Faculty, Victor Chang Cardiac Research Institute
  • Level 3 Cardiac MR- Society of Cardiovascular Magnetic Resonance (2012)
  • Transplantation Society of Australia and New Zealand President’s Prize (2009)
  • Transplantation Society of Australia and New Zealand Young Investigator Award (2009)
  • International Society of Cardiovascular Magnetic Resonance-Early Career Award Finalist (2012)
  • Royal Australasian College of Physicians (NSW) Best Trainee Research Award (2007)
  • St Vincent’s Clinic Clinical Emerging Researcher Award (2009)
  • Cardiovascular Lipid Research Award (2009)
  • National Heart Foundation of Australia – Travel Awards (2007, 2008)
  • Heart Failure Society of America – Young Researcher Travel Award (2005)
  • University of New South Wales Foundation Year Graduates Medal (1999)
  • Multimodality Imaging in Transcatheter Aortic Valve Implantation and Post-Procedural Aortic Regurgitation Comparison Among Cardiovascular Magnetic Resonance, Cardiac Computed Tomography, and Echocardiography. Jabbour A, Ismail T, Moat N et al. J Am Coll Cardiol2011 Nov 15;58(21):2165-73.
  • Association of fibrosis with mortality and sudden cardiac death in patients with non-ischemic dilated cardiomyopathy.  Gulati A, Jabbour A, Ismail TF et al.  JAMA.  2013 Mar 6;309(9):896-908
  • Mid-Wall Fibrosis is an Independent Predictor of Mortality in Patients with Aortic Stenosis. Dweck M, Joshi S,  Murigu T, Alpendurada F, Jabbour A, Melina G, Banya W, Gulati A, Roussin I, Raza S, Prasad N, Wage R, Quarto C, Angeloni E, Refice S, Sheppard M, Cook S, Kilner P, Pennell D, Newby D, Mohiaddin RM, Pepper J, Prasad SK. J Am Coll Cardiol. 2011 Sep 13;58(12):1271-9.
  • Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS. J Am Coll Cardiol. 2010 Apr 27; 55(17):1780-7.
  • Profound Pectus Excavatum in Marfan’s Syndrome. Jabbour A, Zaman S, Ismail T; Prasad S, Mohiaddin RM. LANCET2012 Feb 11;379(9815):557.
  • Clinical utility and prognostic value of left atrial volume assessment by cardiovascular magnetic resonance in non-ischaemic dilated cardiomyopathy.  Gulati A, Ismail T, Jabbour A et al. European Journal of Heart Failure  2013 Mar 8. (Epub ahead of print)
  • Enhanced preservation of pig cardiac allografts by combining erythropoietin with glyceryl trinitrate and zoniporide Watson A, Gao L, Sun L, Tsun J, Doyle A, Faddy S, Jabbour A, Orr Y, Dhital K, Hicks M, Jansz P, Macdonald P et al. American Journal of Transplantation (In press)
  • Monitoring of a Paediatric Cardiac Tumour over Fourteen Years. Jabbour A, Zaman S, Zaman SA, Krishnamoorthy A, Sotubo O, Ismail T, Gulati A, Prasad S. Heart (Epub ahead of print)
  • Enhanced preservation of the rat heart following prolonged hypothermic ischemia with erythropoietin supplemented Celsior. Alasdair J. Watson, Ling Gao, Lin Sun, Jireh Tsun, Andrew Jabbour, Min Qu Riu,  Paul C. Jansz, Mark Hicks, Peter S. Macdonald. J Heart Lung Transplant (2013 Jun;32(6):633-40).
  • A recombinant human neuregulin-1 peptide improves preservation of the rodent heart after prolonged hypothermic storage. Jabbour A, Gao L, Kwan J, Watson A, Sun L, Qiu MR, Liu X, Zhou MD, Graham RM, Hicks M, Macdonald PS. Transplantation. 2011 May 15;91(9):961-7.
  • Inducible myocardial ischaemia diagnosed using computed tomography dipyridamole stress myocardial perfusion technique. Jabbour A, Boshell D, Sesel K, Silverstone E, Muller D, Stirrup J, Rubens M, Hayward CS, Wright SP. J Med Imaging Radiat Oncol. 2012 Aug;56(4):445-8.
  • Left ventricular remodeling and hypertrophy in patients with aortic stenosis: insights from cardiovascular magnetic resonance. Dweck MR, Joshi S, Murigu T, Gulati A, Alpendurada F, Jabbour A, Maceira A, Roussin I, Northridge DB, Kilner PJ, Cook SA, Boon NA, Pepper J, Mohiaddin RH, Newby DE, Pennell DJ, Prasad SK. J Cardiovasc Magn Reson. 2012 Jul 28;14:50.
  • In-vivo Comparison of Myocardial T1 with T2 and T2* in Thalassaemia Major. Taigang He, Carpenter JP, Jabbour A et al. Journal of Magnetic Resonance Imaging. 2013 Jan 31 (Epub ahead of Print).
  • Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Jabbour A, Hayward CS, Keogh AM, Kotlyar E, McCrohon JA, England JF, Amor R, Liu X, Li XY, Zhou MD, Graham RM, Macdonald PS. Eur J Heart Fail. 2011 Jan; 13(1):83-92.
  • Chronic sildenafil lowers transpulmonary gradient and improves cardiac output allowing successful heart transplantation. Jabbour A, Keogh A, Hayward C, Macdonald P.  Eur J Heart Fail. 2007 Jun-Jul; 9(6-7):674-7.
  • Keogh AM, Jabbour A, Hayward CS, Weintraub R, Macdonald PS. Transitioning from Trepostinil to Sildenafil in Patients with Pulmonary Arterial Hypertension. J Heart Lung Transplant. 2007 Nov; 26(11):1079-83.
  • Keogh AM, Jabbour A, Hayward CS, Macdonald PS. Clinical Deterioration after Sildenafil Cessation in Patients with Pulmonary Hypertension. Vasc Health Risk Manage. 2007 4(5):1111–13.

Local investigator contribution to international multi-centre studies:

  • Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. Oudiz RJ, Galiè N, Olschewski H et al. ARIES Study Group, St Vincent’s site investigator. J Am Coll Cardiol. 2009  Nov 17;54(21):1971-81.
  • Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. McGoon MD, Frost AE, Oudiz RJ etal. St Vincent’s site investigator . Chest. 2009 Jan;135(1):122-9
  • Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Galiè N, Rubin Lj et al. St Vincent’s site investigator. Lancet. 2008 Jun 21;371(9630):2093-100
  • Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. Benza RL, Mehta S, Keogh A et al. St Vincent’s site investigator. J Heart Lung Transplant. 2007 Jan;26(1):63-9.
  • Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan. Robyn J. Barst, David Langleben, David Badesch et al. St Vincent’s site investigator. J Am Coll Cardiol47: 2049 – 56 (2006).